MariMed Reports Increased Net Loss, $7.3M in IRS Tax Liens, and Debt Restructuring in 2025 Annual Report
MRMD sits 15% above its 52-week low of $0.067.
Summary
MariMed Inc. reported a wider net loss for 2025, disclosed $7.3 million in IRS tax liens, and completed a debt restructuring that includes new notes and potentially dilutive preferred stock.
Key Events · Financing and Capital Events · MRMD
-
Increased Net Loss and Operating Loss
The company's net loss widened to $14.46 million in 2025 from $12.43 million in 2024, and operating income swung to a loss of $2.82 million from a profit of $2.61 million in the prior year.
-
Significant IRS Tax Liens
The IRS filed liens totaling approximately $7.3 million for 2023 and 2025 tax liabilities, requiring MariMed to deposit $100,000 per month into a cash collateral reserve account starting January 2026.
-
Series B Preferred Stock Restructuring
MariMed restructured a $14.2 million Series B Preferred Stock obligation into $8 million in new promissory notes and 26.9 million shares of new Series B Convertible Preferred Stock.
-
Potential Share Dilution
The newly issued Series B Convertible Preferred Stock is convertible on a one-for-one basis into 26.9 million common shares, representing approximately 6.78% potential dilution to current outstanding shares.
Analysis · MRMD · Life Sciences
MariMed Inc.'s 2025 annual report reveals a challenging financial year, marked by a significant increase in net loss and the disclosure of substantial IRS tax liens. The company's net loss widened to $14.46 million in 2025 from $12.43 million in 2024, and operating income swung to a loss of $2.82 million. Furthermore, the IRS has filed liens totaling $7.3 million for past tax liabilities, necessitating monthly cash collateral deposits, which will impact liquidity. While the Series B Preferred Stock restructuring addresses a $14.2 million obligation, it introduces $8 million in new debt and 26.9 million shares of new convertible preferred stock, representing a notable potential dilution. These factors highlight ongoing financial pressures and regulatory challenges within the cannabis industry.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRMD was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $30.5M. The 52-week trading range was $0.07 to $0.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.